Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 43 min ago
Peer-reviewedCC BY-NC-SA 4.0Journal of Clinical and Experimental Hematopathology : JCEH

Biopsy-proven inflammatory pulmonary opacities mimicking lymphoma relapse after CD19 CAR-T-cell therapy

  1. 1Department of Medical Oncology and Hematology, Oita University Faculty of Medicine, Yufu, Japan, Department of Diagnostic Pathology, Oita University Faculty of Medicine, Yufu, Japan

Abstract

Pulmonary lesions that newly emerge after chimeric antigen receptor T-cell therapy may raise immediate concern for lymphoma relapse, especially when they occur at sites of prior disease involvement. We report a patient with refractory diffuse large B-cell lymphoma who developed newly apparent or re-enlarged FDG-avid pulmonary opacities four months after axicabtagene ciloleucel infusion. The lesions appeared at or near prior pulmonary lymphoma-suspected sites, strongly suggesting recurrence. However, transbronchial lung biopsy showed organizing pneumonia-like inflammatory changes with Masson bodies, CD3-positive T-cell infiltration, and no evidence of lymphoma involvement by multiple B-cell markers. Because the patient remained clinically stable and relapse was not supported histologically, systemic corticosteroids and salvage chemotherapy were withheld. The biopsied lesion and the remaining pulmonary opacities regressed spontaneously during follow-up, and complete remission was maintained. This case illustrates that organizing pneumonia-like inflammatory lesions may arise at prior lymphoma-suspected pulmonary sites after CAR-T-cell therapy and closely mimic pulmonary relapse on FDG-PET/CT. When new FDG-avid pulmonary lesions arise after CAR-T-cell therapy, particularly at prior lymphoma sites, tissue confirmation is essential to avoid misdiagnosis and unnecessary treatment escalation.

Related

  1. Two case reports of gastric signet ring cell carcinoma with pulmonary metastasis manifesting as diffuse ground-glass opacities and pleural involvement: an atypical imaging pattern mimicking lung infection
    Translational cancer researchPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  2. Pulmonary Inflammatory Myofibroblastic Tumor Mimicking Septic Pulmonary Embolism Following a Dental Infection
    Yohei Kanzawa, Nobuya Sano, Masataka Ono +3
    Internal MedicinePeer-reviewedCC BY-NC-NDFull textGeneral medicineJ-STAGE
  3. Case Report: SAPHO syndrome mimicking osseous relapse after haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia
    Wenhui Zhang, Xiaolin Ma, Xianglan Liu +6
    Frontiers in medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. EGFR-mutant lung adenocarcinoma featuring massive bronchorrhea, a dominant pulmonary nodule, and migratory ground-glass opacities: a case report and literature review
    Luyan Chen, Bing Yan, Shusen Zheng +1
    BMC Pulmonary MedicinePeer-reviewedCC BY-NC-ND 4.0Full textGeneral medicinePMC
  5. Steroid-resistant Relapse of Autoimmune Pancreatitis with Marked Main Pancreatic Duct Dilatation Mimicking Multifocal Pancreatic Cancer
    Kenji Hirano, Kanami Kondo, Toshifumi Saito +7
    Internal MedicinePeer-reviewedCC BY-NC-NDFull text1 citedGeneral medicineJ-STAGE
BibTeX
@article{okuhiro2026biopsyproven,
  title = {{Biopsy-proven inflammatory pulmonary opacities mimicking lymphoma relapse after CD19 CAR-T-cell therapy}},
  author = {Kazuki Okuhiro and Takumi Nishikawa and Yosuke Kodama and Manami Iwanaga and Takami Haruyama and Oju Katayama and Shuhei Honda and Yui Moroga and Kuniko Takano and Haruto Nishida and Masao Ogata},
  journal = {Journal of Clinical and Experimental Hematopathology : JCEH},
  year = {2026},
  month = sep,
  doi = {10.3960/jslrt.26035},
  url = {https://doi.org/10.3960/jslrt.26035},
  note = {CC BY-NC-SA 4.0},
}
RIS
TY  - JOUR
TI  - Biopsy-proven inflammatory pulmonary opacities mimicking lymphoma relapse after CD19 CAR-T-cell therapy
AU  - Kazuki Okuhiro
AU  - Takumi Nishikawa
AU  - Yosuke Kodama
AU  - Manami Iwanaga
AU  - Takami Haruyama
AU  - Oju Katayama
AU  - Shuhei Honda
AU  - Yui Moroga
AU  - Kuniko Takano
AU  - Haruto Nishida
AU  - Masao Ogata
PY  - 2026
DA  - 2026/09/30
JO  - Journal of Clinical and Experimental Hematopathology : JCEH
DO  - 10.3960/jslrt.26035
UR  - https://doi.org/10.3960/jslrt.26035
AB  - Pulmonary lesions that newly emerge after chimeric antigen receptor T-cell therapy may raise immediate concern for lymphoma relapse, especially when they occur at sites of prior disease involvement. We report a patient with refractory diffuse large B-cell lymphoma who developed newly apparent or re-enlarged FDG-avid pulmonary opacities four months after axicabtagene ciloleucel infusion. The lesions appeared at or near prior pulmonary lymphoma-suspected sites, strongly suggesting recurrence. However, transbronchial lung biopsy showed organizing pneumonia-like inflammatory changes with Masson bodies, CD3-positive T-cell infiltration, and no evidence of lymphoma involvement by multiple B-cell markers. Because the patient remained clinically stable and relapse was not supported histologically, systemic corticosteroids and salvage chemotherapy were withheld. The biopsied lesion and the remaining pulmonary opacities regressed spontaneously during follow-up, and complete remission was maintained. This case illustrates that organizing pneumonia-like inflammatory lesions may arise at prior lymphoma-suspected pulmonary sites after CAR-T-cell therapy and closely mimic pulmonary relapse on FDG-PET/CT. When new FDG-avid pulmonary lesions arise after CAR-T-cell therapy, particularly at prior lymphoma sites, tissue confirmation is essential to avoid misdiagnosis and unnecessary treatment escalation.
SN  - 1346-4280
SN  - 1880-9952
ER  -